Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Conditions
Keywords
Drug Therapy
Brief summary
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 previous chemotherapy regimens.
Detailed description
The drug being tested in this study is called niraparib. Niraparib is being tested to treat people who have the homologous recombination deficiency (HRD)-positive, advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This study will look at the efficacy and safety of niraparib in Japanese participants. The study will enroll approximately 16 participants. Participants will be enrolled to one group and after that will be asked to take niraparib capsules at the same time each day throughout the study: \- Niraparib 300 mg This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately 23 months. Participants will make multiple visits to the clinic in the treatment period, and the post-treatment period including follow-up assessments after the last dose of the study drug.
Interventions
DRUGNiraparib
Niraparib capsule
Sponsors
Takeda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Japanese female participants aged 20 years or older on the day of signing informed consent. 2. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 3. Participants must agree to undergo tumor homologous recombination deficiency/deficient (HRD) testing, and this test result must show that participants have an HRD-positive tumor (defined by the presence of a deleterious or suspected deleterious breast cancer gene (BRCA) mutation or be positive for genomic instability) by the central laboratory selected by the sponsor. Note 1: The study HRD test result must be received prior to enrollment. The tumor sample may be submitted for HRD testing prior to the screening period (ie, within 40 days before Cycle 1 Day 1) if the consent has been obtained and it appears the participant is likely to meet other eligibility requirements. Note 2: If historic blood germline BRCA mutation (gBRCAmut) is detected by a prior gBRCAmut testing, then tumor HRD sample test results are not required prior to enrollment; however, HRD testing still needs to be performed. 4. Participants must have histologically diagnosed, relapsed, high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and have not experienced disease progression at least 6 months to the last chemotherapy containing platinum-based anticancer agents. 5. Participants must have completed 3 or 4 previous chemotherapy regimens. Participants must have completed their last chemotherapy regimen \>4 weeks prior to treatment initiation. 6. Participants must have at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1). 7. Participants must have performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. 8. Participants must have adequate organ function as indicated by the following laboratory values: * Absolute neutrophil count (ANC) ≥1,500/μL. * Platelet count ≥150,000/μL. * Hemoglobin ≥10 g/dL. * Serum creatinine ≤1.5× institutional upper limit of normal (ULN) OR calculated creatinine clearance ≥50 mL/minute, using the Cockcroft-Gault equation. * Total bilirubin ≤1.5×ULN OR direct bilirubin ≤1×ULN. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN unless liver metastases were present, in which case they had to be ≤5×ULN. 9. Participants must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment initiation. 10. Participants must be able to take oral medications. 11. Female participants of childbearing potential must be negative for pregnancy test (beta-human chorionic gonadotropin \[β-hCG\]) within 7 days prior to receiving the first dose of study treatment. 12. Female participants who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods\], condoms only, withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)
Exclusion criteria
1. Participants who have had palliative radiotherapy encompassing \>20% of the bone marrow within 1 week of the first dose of study treatment. 2. Participants who have any known, persistent (\>4 weeks), Grade ≥3 hematologic toxicity from last cancer therapy. 3. Participants who have any known, persistent (\>4 weeks), Grade ≥3 fatigue during the last cancer therapy. 4. Participants who have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment. 5. Participants who have symptomatic, uncontrolled brain or leptomeningeal metastases. To be considered controlled, central nervous system (CNS) disease must have undergone treatment (eg, radiation or chemotherapy) at least 1 month prior to study enrollment. The participant must not have had any new or progressive signs or symptoms related to the CNS disease and must have been taking a stable dose of steroids or no steroids (as long as these were started at least 4 weeks prior to enrollment\] or no steroids). A scan to confirm the absence of brain metastases at baseline was not required. Participants with spinal cord compression might have been considered if they had received definitive treatment for this and evidence of clinically stable disease for 28 days. 6. Participants who have known hypersensitivity to the components of niraparib. 7. Participants who have had prior treatment with a known poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitors. 8. Participant who have had treatment with any investigational products within 28 days or 5 half-lives (whichever was longer) before the first dose. 9. Participants who have had major surgery per Investigator judgment within 3 weeks of the first dose. Participant must have recovered from any effects of any major surgery. 10. Participants who have diagnosis, detection, or treatment of invasive second primary malignancy other than ovarian cancer ≤24 months prior to study enrollment (except basal or squamous cell carcinoma of the skin that was definitively treated). Note: Participants must not have any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), irrespective of the time for disease history. 11. Participants who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days of the first dose) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, small bowel obstruction or other serious gastrointestinal disorder, or any psychiatric disorder that prohibits obtaining informed consent. 12. Participants who have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment. 13. Participants who have received a live virus or bacterial vaccines within 4 weeks of the first dose of study treatment. 14. Participants who have a history or current evidence of any condition, therapy, or lab abnormality (including active or uncontrolled myelosuppression \[ie, anemia, leukopenia, neutropenia, thrombocytopenia\]) that might confound the results of the study, interfere with the participant's participation throughout the study period, or study participation is not in the best interest of the participant. 15. Participants who are regular user (including recreational use) of any illicit drugs at the time of signing informed consent or have a recent history (within the past year) of drug or alcohol abuse. 16. Participants who are pregnant or breast-feeding or expecting to conceive within the planned duration of the study. NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the study. 17. Participants who are immunocompromised (participants with splenectomy are allowed). 18. Participants who have known human immunodeficiency virus (HIV) positive. 19. Participants who have known hepatitis B surface antigen (HBsAg) positive, or known or suspected active hepatitis C virus (HCV) infection. NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus (HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must have an undetectable HCV viral load.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Until disease progression or death (Up to 3.8 years) | ORR was defined as the percentage of participants achieving CR or PR as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | Until disease progression or death (Up to 3.8 years) | DCR was defined as the percentage of participants achieving CR, PR or SD as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. |
| Number of Participants With Grade 3 or Higher TEAEs | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. |
| Number of Participants With Serious TEAEs | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. |
| Duration of Response (DOR) | Until disease progression or death (Up to 3.8 years) | DOR was defined as the time from the first documented CR or PR per RECIST v.1.1 to disease recurrence or objective disease progression whichever occurs first. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. |
| Number of Participants With TEAEs Leading to Dose Interruption | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. |
| Number of Participants With TEAEs Leading to Dose Reduction | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. |
| Progression Free Survival (PFS) | Until disease progression or death (Up to 3.8 years) | PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death as assessed by the RECIST v.1.1. Per RECIST 1.1, PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. |
| Overall Survival (OS) | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | OS was defined as the time in months from the study enrollment to death due to any cause. |
| Number of Participants With TEAEs Leading to Drug Discontinuation | From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years) | An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. |
Countries
Japan
Participant flow
Recruitment details
Participants took part in the study at 17 investigative sites in Japan from 26 December 2018 to 28 December 2022.
Pre-assignment details
Female participants with a diagnosis of advanced, relapsed, high-grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 prior lines of anti-cancer therapy and are platinum-sensitive to the last platinum-based therapy were enrolled to receive niraparib 300 mg in this study.
Participants by arm
| Arm | Count |
|---|---|
| Niraparib 300 mg Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle for up to 50 cycles. | 20 |
| Total | 20 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 2 |
| Overall Study | Progressive Disease | 15 |
| Overall Study | Site Terminated by Sponsor | 3 |
Baseline characteristics
| Characteristic | Niraparib 300 mg |
|---|---|
| Age, Continuous | 62.4 years STANDARD_DEVIATION 10.69 |
| Body Mass Index (BMI) | 22.12 kilograms per meter square (kg/m^2) STANDARD_DEVIATION 4.074 |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IA | 1 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IC | 1 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IIB | 1 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IIC | 1 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IIIA | 1 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IIIC | 12 Participants |
| Cancer Stage (FIGO) at Time of Initial Diagnosis IV | 3 Participants |
| Duration between End Date of the Last Platinum-based Therapy and the First Dose of Study Treatment | 16.3 months |
| Duration between the End Date of the Last Chemotherapy Regimen and the First Dose of Study Treatment | 2.1 months |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 | 15 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 | 5 Participants |
| Genomic Instability Status Positive | 17 Participants |
| Genomic Instability Status Unknown | 3 Participants |
| Germline BRCA2 Mutant Unknown | 17 Participants |
| Germline BRCA2 Mutant Without Mutant | 3 Participants |
| Germline Breast Cancer (Gene) (BRCA1) Mutant Unknown | 17 Participants |
| Germline Breast Cancer (Gene) (BRCA1) Mutant Without Mutant | 3 Participants |
| Height | 155.9 centimeters (cm) STANDARD_DEVIATION 5.78 |
| Homologous Recombination Deficiency/Deficient (HRD) Companion Diagnostic (CDx) Test Result Positive | 20 Participants |
| Number of Prior Lines of Chemotherapy 3 | 12 Participants |
| Number of Prior Lines of Chemotherapy 4 | 8 Participants |
| Number of Prior Surgery/Procedure for Study Indication | 2.3 surgery STANDARD_DEVIATION 1.34 |
| Ovarian Cancer Pathology Histological: Histologic Subtype Endometrioid | 0 Participants |
| Ovarian Cancer Pathology Histological: Histologic Subtype Mucinous | 0 Participants |
| Ovarian Cancer Pathology Histological: Histologic Subtype Other | 0 Participants |
| Ovarian Cancer Pathology Histological: Histologic Subtype Serous | 20 Participants |
| Ovarian Cancer Pathology Histological: Tumor Grade Grade 2 | 1 Participants |
| Ovarian Cancer Pathology Histological: Tumor Grade Grade 3 | 6 Participants |
| Ovarian Cancer Pathology Histological: Tumor Grade High Grade | 13 Participants |
| Primary Tumor Site Fallopian Tube | 2 Participants |
| Primary Tumor Site Ovarian | 13 Participants |
| Primary Tumor Site Primary Peritoneal | 5 Participants |
| Prior Bevacizumab Participants Who Did Not Receive Bevacizumab | 10 Participants |
| Prior Bevacizumab Participants Who Received Bevacizumab | 10 Participants |
| Prior Doxorubicin Participants Who Did Not Receive Doxorubicin | 11 Participants |
| Prior Doxorubicin Participants Who Received Doxorubicin | 9 Participants |
| Prior Gemcitabine Participants Who Did Not Receive Gemcitabine | 9 Participants |
| Prior Gemcitabine Participants Who Received Gemcitabine | 11 Participants |
| Prior Liposomal Doxorubicin Participants Who Did Not Receive Liposomal Doxorubicin | 20 Participants |
| Prior Radiation Therapy Related to the Study Indication Had No Radiation Therapy | 18 Participants |
| Prior Radiation Therapy Related to the Study Indication Had Radiation Therapy | 2 Participants |
| Prior Surgery/Procedure for Study Indication Participants Who Had Prior Surgery | 20 Participants |
| Prior Taxane Participants Who Received Taxane | 20 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 20 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment Japan | 20 Participants |
| Response to Last Platinum-based Therapy Complete Response (CR) | 9 Participants |
| Response to Last Platinum-based Therapy Partial Response (PR) | 8 Participants |
| Response to Last Platinum-based Therapy Stable Disease (SD) | 2 Participants |
| Response to Last Platinum-based Therapy Unknown | 1 Participants |
| Sex: Female, Male Female | 20 Participants |
| Sex: Female, Male Male | 0 Participants |
| Time from First Diagnosis to First Dose | 4.71 years |
| Time to Progression after the Last Platinum Therapy 6-12 Month | 12 Participants |
| Time to Progression after the Last Platinum Therapy More Than 12 Month | 8 Participants |
| Tumor BRCA1/BRCA2 Mutation Status Negative | 6 Participants |
| Tumor BRCA1/BRCA2 Mutation Status Positive | 13 Participants |
| Tumor BRCA1/BRCA2 Mutation Status Unknown | 1 Participants |
| Weight | 53.70 kilograms (kg) STANDARD_DEVIATION 9.701 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 13 / 20 |
| other Total, other adverse events | 20 / 20 |
| serious Total, serious adverse events | 8 / 20 |
Outcome results
Primary
Objective Response Rate (ORR)
ORR was defined as the percentage of participants achieving CR or PR as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.
Time frame: Until disease progression or death (Up to 3.8 years)
Population: FAS included all participants who received at least 1 dose of study drug and have measurable disease at Baseline.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Niraparib 300 mg | Objective Response Rate (ORR) | 60.0 percentage of participants |
Secondary
Disease Control Rate (DCR)
DCR was defined as the percentage of participants achieving CR, PR or SD as assessed by the Investigator per RECIST v.1.1. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.
Time frame: Until disease progression or death (Up to 3.8 years)
Population: FAS included all participants who received at least 1 dose of study drug and have measurable disease at Baseline.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Niraparib 300 mg | Disease Control Rate (DCR) | 90.0 percentage of participants |
Secondary
Duration of Response (DOR)
DOR was defined as the time from the first documented CR or PR per RECIST v.1.1 to disease recurrence or objective disease progression whichever occurs first. CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD.
Time frame: Until disease progression or death (Up to 3.8 years)
Population: FAS included all participants who received at least 1 dose of study drug and have measurable disease at Baseline. Only Responders were analyzed for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Niraparib 300 mg | Duration of Response (DOR) | 9.9 months |
Secondary
Number of Participants With Grade 3 or Higher TEAEs
An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With Grade 3 or Higher TEAEs | 17 Participants |
Secondary
Number of Participants With Serious TEAEs
An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With Serious TEAEs | 8 Participants |
Secondary
Number of Participants With TEAEs Leading to Dose Interruption
An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With TEAEs Leading to Dose Interruption | 15 Participants |
Secondary
Number of Participants With TEAEs Leading to Dose Reduction
An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With TEAEs Leading to Dose Reduction | 16 Participants |
Secondary
Number of Participants With TEAEs Leading to Drug Discontinuation
An AE was defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With TEAEs Leading to Drug Discontinuation | 2 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Niraparib 300 mg | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 20 Participants |
Secondary
Overall Survival (OS)
OS was defined as the time in months from the study enrollment to death due to any cause.
Time frame: From first dose of study drug up to 30 days after the last dose or beginning of subsequent anticancer therapy, whichever came first (Up to 3.8 years)
Population: FAS included all participants who received at least 1 dose of study drug and have measurable disease at Baseline.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Niraparib 300 mg | Overall Survival (OS) | 24.9 months |
Secondary
Progression Free Survival (PFS)
PFS was defined as the time in months from the date of first study drug administration to the date of first documentation of PD or death as assessed by the RECIST v.1.1. Per RECIST 1.1, PD was defined as at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline.
Time frame: Until disease progression or death (Up to 3.8 years)
Population: FAS included all participants who received at least 1 dose of study drug and have measurable disease at Baseline.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Niraparib 300 mg | Progression Free Survival (PFS) | 8.3 months |